Table 5.
Distribution of the degree to which physicians are being affected by each product strategy
| No | Description | Strongly agree | Agree | Neutral | Disagree | Strongly disagree |
|---|---|---|---|---|---|---|
| 1 | Country of pharmaceutical product manufacturer | 24.2% | 48.7% | 20.4% | 4.2% | 2.6% |
| 2 | Image of pharmaceutical company | 24.2% | 50.2% | 20.0% | 3.4% | 2.3% |
| 3 | Supportive evidence of the efficacy of the medicine given by pharmaceutical company | 50.9% | 37.7% | 8.3% | 2.3% | 0.8% |
| 4 | Release of new innovations or combinations of drugs | 45.7% | 41.1% | 10.2% | 2.6% | 0.4% |
| 5 | Form of delivery of the medicine | 38.1% | 41.5% | 15.8% | 3.0% | 1.5% |
| 6 | Easy to remember brand names | 40.0% | 34.7% | 18.9% | 5.3% | 1.1% |
| 7 | Reputation of the source of medicine | 44.2% | 40.8% | 12.5% | 2.3% | 0.4% |
| 8 | Quality of medicine | 72.1% | 19.6% | 6.0% | 1.5% | 0.8% |
| 9 | Fixed-dose packaging of the product | 34.7% | 42.6% | 17.0% | 2.6% | 3.0% |
| 10 | Full therapy packaging | 44.2% | 39.2% | 13.2% | 0.8% | 2.6% |